The global spectrum of protein-coding pharmacogenomic diversity
Citations Over TimeTop 10% of 2016 papers
Abstract
Differences in response to medications have a strong genetic component. By leveraging publically available data, the spectrum of such genomic variation can be investigated extensively. Pharmacogenomic variation was extracted from the 1000 Genomes Project Phase 3 data (2504 individuals, 26 global populations). A total of 12 084 genetic variants were found in 120 pharmacogenes, with the majority (90.0%) classified as rare variants (global minor allele frequency ST>0.5) for one or more super-population comparison. A median of three clinical variants (PharmGKB level 1A/B) was found per individual, and 55.4% of individuals carried loss-of-function variants, varying by super-population (East Asian 60.9%>African 60.1%>South Asian 60.3%>European 49.3%>Admixed 39.2%). Genome sequencing can therefore identify clinical pharmacogenomic variation, and future studies need to consider rare variation to understand the spectrum of genetic diversity contributing to drug response.
Related Papers
- → Performance of Genotype Imputation for Low Frequency and Rare Variants from the 1000 Genomes(2015)70 cited
- → A systematic approach to the assessment of known TNF-α polymorphisms in Graves' disease(2004)40 cited
- → Allele frequency determination of publicly available cSNPs in the Korean population(2002)2 cited
- Comparing genomic relationship matrices with relationship estimated from pedigree data.(2013)
- → A powerful allele based test for case-control association studies(2015)